Our Team

Aruni S. Arachchige Don, PhD
Senior Consultant

Aruni S. Arachchige Don, PhD

Senior Consultant

Aruni is a Senior Consultant and Project Lead for Payer/Market Access. Aruni has contributed to projects that span the therapeutic landscape and leads the respiratory disease franchise at DH. Aruni received a PhD in Pharmacology. Prior to DH, Aruni completed a postdoctoral fellowship in collaboration with the W.M. Keck Center for Collaborative Neuroscience.

Jeffrey M. Bockman, PhD
EVP, Head of Oncology Practice

Jeffrey M. Bockman, PhD

EVP, Head of Oncology Practice

Jeff Leads the Oncology at DH, the firm’s largest practice area. He earned his PhD from Berkeley in Molecular Virology, working on prions, and completed a post-doc at The George Washington School of Medicine. His first stint in industry was at a start-up biotech working on oligonucleotide therapeutics for cancer and infectious diseases.

Janet Czachura
Principal

Janet Czachura

Principal

Janet leads the Search and Evaluation Practice at DH, and has over 30 years of scientific and pharmaceutical experience. Her background includes academia and global large pharma, with experience in partnering & research acquisition, competitive strategic analysis, regulatory, and knowledge management.

Ginger S. Johnson, PhD
Chief Executive Officer

Ginger S. Johnson, PhD

Chief Executive Officer

Ginger is CEO and CNS Practice Co-Lead. Her background ranges from basic scientific research to private equity investment. Ginger was a Director at Chase Capital Partners private equity firm, Associate Director of the Center for Biotechnology at Northwestern University and conducted basic and applied research at the National Institute of Mental Health.

James T. Lee, PhD
Associate Principal

James T. Lee, PhD

Associate Principal

James has 10 years of experience in the oncology space spread across academic research, biotech, and business and clinical development strategy consulting. He is currently helping to lead the oncology practice alongside other senior oncology team members.

Ginny E. Llobell
Senior VP, Business Development and Marketing

Ginny E. Llobell

Senior VP, Business Development and Marketing

Ginny has held senior level positions in Business Development, Corporate Development, Strategy, Marketing, and Operations over the course of her 30+ year career in the Life Sciences, at Itohchu, The Center for Biotechnology at Stony Brook University and Defined Health. She earned a BS with distinction from Cornell University

David J. Lomb, PhD
Associate Principal

David J. Lomb, PhD

Associate Principal

David co-leads the autoimmune and inflammatory disease, and leads the fibrosis and ophthalmology practices at DH. He earned a PhD in Pharmacology from University of Rochester where his thesis focused on neuronal programmed cell death, and completed a postdoctoral fellowship in the Paul F. Glenn Laboratories for Biological Mechanisms of Aging at Harvard Medical School.

Danielle M. Marra, MS, MBA
Associate Principal

Danielle M. Marra, MS, MBA

Associate Principal

Danielle manages projects focused on opportunity assessments and therapeutic area growth strategy. She co-leads the autoimmune and inflammatory disease practice and leads the antibiotics therapeutic area. Danielle earned a MBA and Master’s degree in Molecular Biology from Rutgers University. Prior to joining DH, Danielle spent time in research at a biotech company.

Brent W. Osborne, PhD
Consultant

Brent W. Osborne, PhD

Consultant

Brent has over 8 years of life sciences experience with a recent focus on consulting within the cardiometabolic and rare disease therapeutic areas. Brent’s Ph.D. (University of Vermont) and postdoctoral fellowship (Columbia University) focused on the identification of novel drug targets for hypertension and other cardiovascular disorders.

Michael C. Rice, MS, MBA
Principal

Michael C. Rice, MS, MBA

Principal

Mike is the head of DH’s Advanced Therapies and Rare Diseases practices. He has
20 years’ experience in biotech ventures defining strategic development and early commercial strategy for academic and biotech inventions pertaining to nucleic acids, gene therapy and cellular platforms applied across monogenetic diseases and oncology. Mike holds an MBA, and is a member of ASGCT, ARM, SITC, ASCO, ASH, LES, and AHA.

Ed Saltzman
Executive Chairman

Ed Saltzman

Executive Chairman

Ed leverages his 30+ years of experience working at the intersection of science and strategy to deliver value driving advice to early stage biotech companies.

Joel S. Sandler, PhD
Associate Principal

Joel S. Sandler, PhD

Associate Principal

Joel applies analytic focus and relentless curiosity honed over years as a business development executive and PhD-trained scientist to deliver client-centric solutions towards the effective positioning and partnering of therapeutic candidates being developed within competitive oncology and CNS landscapes.